

Supplementary Table 1: Patients and tumors characteristics

	Training set (n=63)			Validation set (n=61)		
	IMPC (n=37)	ICNST (n=26)	<i>p</i> -val	IMPC (n=36)	ICNST (n=25)	<i>p</i> -val
follow-up (months)						
med, intervalle	137 [18-505]	43 [1-124]		97 [13-320]	51 [4-155]	
age at diagnosis (yrs)						
med, intervalle	56 [36-84]	58 [27-85]		61 [34-84]	56 [38-78]	
< 50	12	7	<i>ns</i>	6	7	<i>ns</i>
≥ 50	25	19		30	18	
ER						
+	34	26	<i>ns</i>	32	25	<i>ns</i>
-	3	0		4	0	
ERBB2						
3 ⁺	6	16	<i>ns</i>	8	14	<i>ns</i>
ND	2	1		0	0	
N						
+	22	20	<i>ns</i>	20	18	<i>ns</i>
-	14	4		14	5	
ND	1	2		2	2	
LVI						
+	29	18	<i>ns</i>	26	18	<i>ns</i>
-	8	8		10	7	
Grade						
1	3	3	<i>ns</i>	2	3	<i>ns</i>
2	15	8		18	8	
3	17	15		15	14	
ND	2	0		1	0	

ER: estrogen receptor - N: axillary lymph node invasion - LVI: lympho vascular invasion
 ND: not done - *ns*: not significant - med: median - yrs: years